Reports Q4 revenue $2.77M, consensus $2.31M. Cash, cash equivalents and marketable securities totaled $610.7M as of December 31, 2022, which reflects $344.6M raised in 2022, inclusive of $223.8M of net proceeds from our follow-on financing. "In 2022, we executed on our goal of advancing three rare disease programs into clinical development and demonstrated the first-ever successful targeted delivery of RNA into muscle, a revolutionary advancement for the field of RNA therapeutics," said Sarah Boyce, president and CEO. "Building on our AOC proof of platform data, 2023 will be another important year for Avidity. We look forward to Phase 1/2 MARINA and MARINA-OLE data as well as results from healthy volunteers in the Phase 1/2 EXPLORE44(TM) trial while continuing to expand the broad utility of our AOC platform."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RNA:
- Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlights
- Avidity Biosciences advances RNA programs, expands into new therapeutic areas
- Dyne Therapeutics upgraded to Strong Buy from Outperform at Raymond James
- Avidity Biosciences’ AOC 1020 granted Orphan Drug designation in FSHD
- Avidity Biosciences treatment of FSHD granted orphan designation
